Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy

Many potentially therapeutic molecules have been identified for treating Duchenne muscular dystrophy. However, targeting those molecules only to sites of active pathology is an obstacle to their clinical use. Because dystrophic muscles become extensively inflamed, we tested whether expressing a ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Welc, Steven S., Flores, Ivan, Wehling-Henricks, Michelle, Ramos, Julian, Wang, Ying, Bertoni, Carmen, Tidball, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594976/
https://www.ncbi.nlm.nih.gov/pubmed/31243277
http://dx.doi.org/10.1038/s41467-019-10614-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594976/
https://www.ncbi.nlm.nih.gov/pubmed/31243277
http://dx.doi.org/10.1038/s41467-019-10614-1

Ejemplares similares